E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10084270 |
E.1.2 | Term | SARS-CoV-2 acute respiratory disease |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate the efficacy of C21 versus placebo as add on to Standard of Care on recovery in subjects with COVID-19. |
|
E.2.2 | Secondary objectives of the trial |
• Evaluate the safety profile of C21 versus placebo as add on to SoC in subjects with COVID-19. • Characterize the PK profile of C21 in subjects with COVID-19. • Evaluate the efficacy profile of C21 versus placebo as add on to SoC in subjects with COVID-19. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age ≥18 years or the legal age of consent 2. Hospitalized due to SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) test, documented by either of the following: a. PCR positive in sample collected <72 hours prior to randomization (Visit 2); OR b. PCR positive in sample collected ≥72 hours and ≤7 days prior to randomization, documented inability to obtain a repeat sample AND progressive disease suggestive of ongoing SARS-CoV-2 infection. 3. A score of 5 or 6 on the 8-point ordinal scale: a. Score 5: Hospitalized, requiring supplemental oxygen. b. Score 6: Hospitalized, on non-invasive ventilation or high-flow oxygen device. 4. Contraceptive use by men and women of childbearing potential 5. Written informed consent obtained before the initiation of any trial-related procedure. 6. Capable of giving signed informed consent |
|
E.4 | Principal exclusion criteria |
1. Concurrent serious medical condition which in the opinion of the investigator constitutes a risk or a contraindication for the participation in the trial or that could interfere with the trial objectives, conduct or evaluation. 2. Known, active hepatitis B, C, or human immunodeficiency virus (HIV) infection 3. Impaired hepatic function (i.e., Child-Pugh class A or B) 4. Severe renal impairment (i.e., estimated glomerular filtration rate (eGFR) ≤30 ml/min/1.73 m2). 5. COVID-19 symptom onset >14 days prior to screening (Visit 1). 6. Hospitalized due to COVID-19 for >72 hours at screening (Visit 1). 7. Invasive mechanical ventilation or ECMO within 72 hours of screening (Visit 1) 8. Expected need for invasive mechanical ventilation or ECMO in <48 hours in the opinion of the investigator. 9. Moderate to severe ARDS (e.g., PaO2/FiO2 ≤200 mmHg), if on non-invasive mechanical ventilation or high-flow oxygen. 10. Pregnant or breast-feeding female subjects. 11. Any previous and concurrent experimental treatment for COVID-19 that is not considered local SoC. 12. Treatment with the medications listed below within 1 week prior to screening (Visit 1) or anticipated need for such medication during the participation in this trial: a. Strong Cytochrome P450 (CYP) 3A4 inducers. b. P-glycoprotein (P-gp) substrates with narrow therapeutic index. c. High dose BCRP sensitive substrates. d. Warfarin. e. Sulphasalazine or rosuvastatin. 13. Current or previous participation in any other clinical trial where the subject has received a dose of IMP within 1 month or 5 half-lives of the IMP, whichever is longest, prior to screening (Visit 1). 14. Positive pregnancy test 15. Abnormal laboratory value at screening (Visit 1) indicating a potential risk for the subject if enrolled in the trial as evaluated by the investigator. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Proportion of subjects discharged from hospital and free of supplemental oxygen at Day 15. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
• Proportion of subjects discharged from hospital and free of supplemental oxygen at Day 15. |
|
E.5.2 | Secondary end point(s) |
• Supplemental oxygen free days up to Day 29. • Proportion of subjects free of respiratory failure, defined as an 8-point ordinal scale score <6, at Day 15. • Time to sustained hospital discharge up to Day 60. • All-cause mortality up to Day 60. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• Supplemental oxygen free days up to Day 29. • Proportion of subjects free of respiratory failure, defined as an 8-point ordinal scale score <6, at Day 15. • Time to sustained hospital discharge up to Day 60. • All-cause mortality up to Day 60. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Brazil |
Colombia |
India |
Peru |
South Africa |
United States |
Poland |
Argentina |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
last visit of the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |